Biogen gets EU antitrust questions over multiple-sclerosis drug
By Lewis Crofts ( February 6, 2026, 15:49 GMT | Insight) -- US biotech company Biogen is the target of an EU investigation regarding its compliance with antitrust laws for a multiple sclerosis treatment, MLex has learned. Last month, it was quizzed by the European Commission over Tecfidera, a drug that has been subject to fierce litigation over patent protection.US biotech company Biogen is the target of an EU investigation regarding its compliance with antitrust laws for a multiple sclerosis treatment. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.